Nuance (NUAN +6.5%) rallies after stating it has no plans to make a bid for clinical...


Nuance (NUAN +6.5%) rallies after stating it has no plans to make a bid for clinical transcription rival M*Modal (MODL -1.6%), which is set to be purchased by JPMorgan's P-E arm for $14/share. The weak Q2 report delivered yesterday by M*Modal could be a reason why. M*Modal had previously disclosed it turned down a $17/share offer from a competitor widely believed to be Nuance, due to timing and antitrust worries.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs